77 related articles for article (PubMed ID: 35627249)
1.
Zhang HF; Huang SL; Wang WL; Zhou YQ; Jiang J; Dai ZJ
World J Clin Cases; 2024 May; 12(15):2627-2635. PubMed ID: 38817239
[TBL] [Abstract][Full Text] [Related]
2. Two sisters diagnosed with familial paraganglioma syndrome type 1 (FPGL1) and multiple endocrine neoplasia type 2A (MEN2A).
Stawarz K; Durzynska M; Galazka A; Paszkowska M; Bienkowska-Pluta K; Zwolinski J; Tysarowski A; Kwiatkowska E; Podgorska A
World J Surg Oncol; 2024 May; 22(1):139. PubMed ID: 38802890
[TBL] [Abstract][Full Text] [Related]
3. A patient with RET D631Y mutation present with pheochromocytoma.
Kim JM
Clin Case Rep; 2021 Jul; 9(7):e04423. PubMed ID: 34267909
[TBL] [Abstract][Full Text] [Related]
4. Bilateral pheochromocytomas: clinical presentation and morbidity rate related to surgery technique and genetic status.
Lider Burciulescu SM; Gheorghiu ML; Muresan A; Gherlan I; Patocs A; Badiu C
Endocr Connect; 2024 Apr; 13(4):. PubMed ID: 38318817
[TBL] [Abstract][Full Text] [Related]
5. Mutation screening of RET proto-oncogene in a family with medullary thyroid carcinoma, marfanoid habitus and pheochromocytoma; from clinically MEN2B to genetically MEN2A syndrome.
Hasani-Ranjbar S; Amoli MM
Endocrine; 2012 Jan; ():. PubMed ID: 22290487
[No Abstract] [Full Text] [Related]
6. Design of new drugs for medullary thyroid carcinoma.
Li Y; Luo Z; Wang X; Zhang S; Hei H; Qin J
Front Oncol; 2022; 12():993725. PubMed ID: 36544713
[TBL] [Abstract][Full Text] [Related]
7. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K; Raue F
Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
[TBL] [Abstract][Full Text] [Related]
8. RET c.1901G>A and Novel SLC12A3 Mutations in Familial Pheochromocytomas.
Zhao L; Yang KQ; Fan P; Gong DX; Zhang L; Lu YT; Meng X; Zhou XL
Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627249
[TBL] [Abstract][Full Text] [Related]
9. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.
Zhou Y; Zhao Y; Cui B; Gu L; Zhu S; Li J; Liu J; Yin M; Zhao T; Yin Z; Yu C; Chen C; Wang L; Xiao B; Hong J; Zhang Y; Tang Z; Wang S; Li X; Ning G
Clin Endocrinol (Oxf); 2007 Oct; 67(4):570-6. PubMed ID: 17573899
[TBL] [Abstract][Full Text] [Related]
10. [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees].
Zhou YL; Zhu SX; Li JJ; Liu JB; Yin M; Xiao BY; Yu CL; Wang LM; Gu LQ; Cui B; Ning G; Li XY; Zhao YJ
Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):466-70. PubMed ID: 17663821
[TBL] [Abstract][Full Text] [Related]
11. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
Wang J; Zhang B; Liu W; Zhang Y; Di X; Yang Y; Yan D
Fam Cancer; 2016 Jan; 15(1):99-104. PubMed ID: 26254625
[TBL] [Abstract][Full Text] [Related]
12. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
13. Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene.
Peppa M; Boutati E; Kamakari S; Pikounis V; Peros G; Panayiotides IG; Economopoulos T; Raptis SA; Hadjidakis D
Eur J Endocrinol; 2008 Dec; 159(6):767-71. PubMed ID: 18805915
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
